Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cyclacel Pharmaceuticals Inc (CYCC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9960
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, CDK inhibitor and PLK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.

Cyclacel Pharmaceuticals Inc (CYCC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 11
Licensing Agreements 12
Cyclacel Enters into Licensing Agreement with ManRos Therapeutics 12
Equity Offering 13
Cyclacel Pharma to Raise up to USD5 Million in Public Offering of Shares 13
Cyclacel Pharma Raises USD15.2 Million in Public Offering of Units 14
Cyclacel Pharma Raises USD1 Million in Public Offering of Shares 16
Cyclacel Pharma Raises USD2.8 Million in Private Placement of Shares 17
Cyclacel Pharma to Raise up to USD8.35 Million in Private Placement of Shares 18
Cyclacel Pharma Raises USD10 Million in Public Offering of Shares 19
Cyclacel Pharma Completes Public Offering Of Shares For US$10 Million 21
Cyclacel Pharma Completes Public Offering Of Shares For US$20 Million 23
Cyclacel Pharma Completes Private Placement Of Shares For US$3 Million 25
Asset Transactions 26
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 26
Cyclacel Pharmaceuticals Inc – Key Competitors 28
Cyclacel Pharmaceuticals Inc – Key Employees 29
Cyclacel Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 09, 2018: Cyclacel Pharmaceuticals reports second quarter 2018 financial results 31
May 14, 2018: Cyclacel Pharmaceuticals Announces First Quarter 2018 Financial Results 33
Mar 28, 2018: Cyclacel Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results 35
Nov 09, 2017: Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results 38
Aug 09, 2017: Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 40
May 11, 2017: Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results 42
Mar 28, 2017: Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 44
Corporate Communications 46
Sep 12, 2018: Cyclacel Pharmaceuticals names Robert J. Spiegel as Board Director 46
May 22, 2018: CerSci Therapeutics Names Dr. David U’Prichard To Advisory Board 47
Product News 48
09/11/2018: Cyclacel starts Phase lb/ll trial BRCA mutant breast cancer 48
Clinical Trials 49
Feb 21, 2018: Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations 49
Dec 12, 2017: Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting 50
Nov 01, 2017: Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting 52
Apr 02, 2017: Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways 53
Mar 07, 2017: Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI 55
Feb 23, 2017: Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia 56
Other Significant Developments 58
Jan 09, 2018: Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cyclacel Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cyclacel Pharma Enters into Co-Development Agreement with University of Texas MD Anderson Cancer Center 11
Cyclacel Enters into Licensing Agreement with ManRos Therapeutics 12
Cyclacel Pharma to Raise up to USD5 Million in Public Offering of Shares 13
Cyclacel Pharma Raises USD15.2 Million in Public Offering of Units 14
Cyclacel Pharma Raises USD1 Million in Public Offering of Shares 16
Cyclacel Pharma Raises USD2.8 Million in Private Placement of Shares 17
Cyclacel Pharma to Raise up to USD8.35 Million in Private Placement of Shares 18
Cyclacel Pharma Raises USD10 Million in Public Offering of Shares 19
Cyclacel Pharma Completes Public Offering Of Shares For US$10 Million 21
Cyclacel Pharma Completes Public Offering Of Shares For US$20 Million 23
Cyclacel Pharma Completes Private Placement Of Shares For US$3 Million 25
Celgene To Acquire Romidepsin Injection Patents From Cyclacel For US$5.5 Million 26
Cyclacel Pharmaceuticals Inc, Key Competitors 28
Cyclacel Pharmaceuticals Inc, Key Employees 29
Cyclacel Pharmaceuticals Inc, Other Locations 30
Cyclacel Pharmaceuticals Inc, Subsidiaries 30

List of Figures
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cyclacel Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cyclacel Pharmaceuticals Inc (CYCC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wawa Inc:企業の戦略・SWOT・財務情報
    Wawa Inc - Strategy, SWOT and Corporate Finance Report Summary Wawa Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Fresenius Kabi AG:企業の戦略的SWOT分析
    Fresenius Kabi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Osaka University:製薬・医療:M&Aディール及び事業提携情報
    Summary Osaka University (OU) is an educational university that provides undergraduate and graduate courses. The university provides courses in dentistry, economics, engineering, engineering science, foreign studies, human sciences, law and politics, medicine, information science and technology, lan …
  • Allianz Group:企業のM&A・事業提携・投資動向
    Allianz Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allianz Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • The InterTech Group Inc:企業の戦略的SWOT分析
    The InterTech Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Gentiva Health Services Inc-製薬・医療分野:企業M&A・提携分析
    Summary Gentiva Health Services Inc (Gentiva), a subsidiary of Kindred Healthcare Inc is a provider of home health and hospice services. It offers various patient care services at the patient’s home or hospital. Its major services include expert nursing care; disease and pain management; medication …
  • Nexstar Media Group, Inc. (NXST):企業の財務・戦略的SWOT分析
    Nexstar Media Group, Inc. (NXST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Tredegar Corp (TG):企業の財務・戦略的SWOT分析
    Tredegar Corp (TG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Dai Nippon Printing Co., Ltd.:企業の戦略・SWOT・財務分析
    Dai Nippon Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dai Nippon Printing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Universal Display Corp (OLED):企業の財務・戦略的SWOT分析
    Summary Universal Display Corp (UDC) is a clean technology company that conducts research, develops and markets organic light emitting diode, technologies and materials. The company offers PHOLED materials which are used in making OLED displays and lighting panels. It provides technologies such as F …
  • Auris Medical Holding Ltd (EARS):企業の財務・戦略的SWOT分析
    Auris Medical Holding Ltd (EARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Rio Tinto:企業の戦略・SWOT・財務情報
    Rio Tinto - Strategy, SWOT and Corporate Finance Report Summary Rio Tinto - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Reece Ltd (REH):企業の財務・戦略的SWOT分析
    Reece Ltd (REH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PSE Kinsale Energy Ltd:企業の戦略的SWOT分析
    PSE Kinsale Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Shinhan Bank:企業の戦略・SWOT・財務情報
    Shinhan Bank - Strategy, SWOT and Corporate Finance Report Summary Shinhan Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sangui BioTech International Inc (SGBI):企業の財務・戦略的SWOT分析
    Sangui BioTech International Inc (SGBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Korea Aerospace Industries Ltd.:企業の戦略・SWOT・財務情報
    Korea Aerospace Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Korea Aerospace Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Bel Fuse Inc. (BELFA):企業の財務・戦略的SWOT分析
    Bel Fuse Inc. (BELFA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Digirad Corp (DRAD):医療機器:M&Aディール及び事業提携情報
    Summary Digirad Corp (Digirad) is a medical device company that provides mobile and on-site imaging solutions. The company provides camera products such as ergo, cardius x-ACT, cardius 2 XPO, corcam, quantumcam, cardius 3 XPO, and others. It provides diagnostic services such as nuclear cardiology, u …
  • Bank of Japan (8301):企業の財務・戦略的SWOT分析
    Bank of Japan (8301) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆